Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 172

1.

Multiple myeloma: 2013 update on diagnosis, risk-stratification, and management.

Rajkumar SV.

Am J Hematol. 2013 Mar;88(3):226-35. doi: 10.1002/ajh.23390. Erratum in: Am J Hematol. 2014 Jun;89(6):669.

PMID:
23440663
[PubMed - indexed for MEDLINE]
2.

Multiple myeloma: 2014 Update on diagnosis, risk-stratification, and management.

Vincent Rajkumar S.

Am J Hematol. 2014 Oct;89(10):999-1009. doi: 10.1002/ajh.23810. Review.

PMID:
25223428
[PubMed - indexed for MEDLINE]
3.

Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management.

Rajkumar SV.

Am J Hematol. 2012 Jan;87(1):78-88. doi: 10.1002/ajh.22237. Erratum in: Am J Hematol. 2012 Apr;87(4):452. Am J Hematol. 2014 Jun;89(6):669.

PMID:
22180161
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management.

Rajkumar SV.

Am J Hematol. 2011 Jan;86(1):57-65. doi: 10.1002/ajh.21913. Review. Erratum in: Am J Hematol. 2014 Jun;89(6):669.

PMID:
21181954
[PubMed - indexed for MEDLINE]
5.

Treatment of newly diagnosed myeloma.

Palumbo A, Rajkumar SV.

Leukemia. 2009 Mar;23(3):449-56. doi: 10.1038/leu.2008.325. Epub 2008 Nov 13. Review.

PMID:
19005483
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myeloma.

Khan ML, Reeder CB, Kumar SK, Lacy MQ, Reece DE, Dispenzieri A, Gertz MA, Greipp P, Hayman S, Zeldenhurst S, Dingli D, Lust J, Russell S, Laumann KM, Mikhael JR, Leif Bergsagel P, Fonseca R, Vincent Rajkumar S, Keith Stewart A.

Br J Haematol. 2012 Feb;156(3):326-33. doi: 10.1111/j.1365-2141.2011.08949.x. Epub 2011 Nov 23.

PMID:
22107129
[PubMed - indexed for MEDLINE]
7.

Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study.

Cavo M, Tacchetti P, Patriarca F, Petrucci MT, Pantani L, Galli M, Di Raimondo F, Crippa C, Zamagni E, Palumbo A, Offidani M, Corradini P, Narni F, Spadano A, Pescosta N, Deliliers GL, Ledda A, Cellini C, Caravita T, Tosi P, Baccarani M; GIMEMA Italian Myeloma Network.

Lancet. 2010 Dec 18;376(9758):2075-85. doi: 10.1016/S0140-6736(10)61424-9. Epub 2010 Dec 9. Erratum in: Lancet. 2011 Nov 26;378(9806):1846.

PMID:
21146205
[PubMed - indexed for MEDLINE]
8.

Update on risk stratification and treatment of newly diagnosed multiple myeloma.

Kapoor P, Rajkumar SV.

Int J Hematol. 2011 Oct;94(4):310-20. doi: 10.1007/s12185-011-0947-z. Epub 2011 Oct 18. Review.

PMID:
22005834
[PubMed - indexed for MEDLINE]
9.

Treatment of multiple myeloma: a comprehensive review.

Kyle RA, Rajkumar SV.

Clin Lymphoma Myeloma. 2009 Aug;9(4):278-88. doi: 10.3816/CLM.2009.n.056. Review.

PMID:
19717377
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Treatment of multiple myeloma: 2009 update.

[No authors listed]

Prescrire Int. 2009 Dec;18(104):263-6.

PMID:
20025098
[PubMed - indexed for MEDLINE]
11.

Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results.

Gay F, Magarotto V, Crippa C, Pescosta N, Guglielmelli T, Cavallo F, Pezzatti S, Ferrari S, Liberati AM, Oliva S, Patriarca F, Offidani M, Omedé P, Montefusco V, Petrucci MT, Giuliani N, Passera R, Pietrantuono G, Boccadoro M, Corradini P, Palumbo A.

Blood. 2013 Aug 22;122(8):1376-83. doi: 10.1182/blood-2013-02-483073. Epub 2013 Jun 17. Erratum in: Blood. 2014 Jun 12;123(24):3843.

PMID:
23775712
[PubMed - indexed for MEDLINE]
Free Article
12.

Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma.

Moreau P, Avet-Loiseau H, Facon T, Attal M, Tiab M, Hulin C, Doyen C, Garderet L, Randriamalala E, Araujo C, Lepeu G, Marit G, Caillot D, Escoffre M, Lioure B, Benboubker L, Pégourié B, Kolb B, Stoppa AM, Fuzibet JG, Decaux O, Dib M, Berthou C, Chaleteix C, Sebban C, Traullé C, Fontan J, Wetterwald M, Lenain P, Mathiot C, Harousseau JL.

Blood. 2011 Nov 24;118(22):5752-8; quiz 5982. doi: 10.1182/blood-2011-05-355081. Epub 2011 Aug 17.

PMID:
21849487
[PubMed - indexed for MEDLINE]
Free Article
13.

Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma.

Eom HS, Min CK, Cho BS, Lee S, Lee JW, Min WS, Kim CC, Kim M, Kim Y.

Jpn J Clin Oncol. 2009 Jul;39(7):449-55. doi: 10.1093/jjco/hyp046. Epub 2009 Jun 1.

PMID:
19487425
[PubMed - indexed for MEDLINE]
Free Article
14.

Sequential bortezomib, dexamethasone, and thalidomide maintenance therapy after single autologous peripheral stem cell transplantation in patients with multiple myeloma.

Sahebi F, Frankel PH, Farol L, Krishnan AY, Cai JL, Somlo G, Thomas SH, Reburiano E, Popplewell LL, Parker PM, Spielberger RT, Kogut NM, Karanes C, Htut M, Ruel C, Duarte L, Murata-Collins JL, Forman SJ.

Biol Blood Marrow Transplant. 2012 Mar;18(3):486-92. doi: 10.1016/j.bbmt.2011.12.580. Epub 2011 Dec 22.

PMID:
22198542
[PubMed - indexed for MEDLINE]
15.

Intermediate-dose melphalan (100 mg/m2)/bortezomib/thalidomide/dexamethasone and stem cell support in patients with refractory or relapsed myeloma.

Palumbo A, Avonto I, Bruno B, Falcone A, Scalzulli PR, Ambrosini MT, Bringhen S, Gay F, Rus C, Cavallo F, Falco P, Massaia M, Musto P, Boccadoro M.

Clin Lymphoma Myeloma. 2006 May;6(6):475-7.

PMID:
16796778
[PubMed - indexed for MEDLINE]
16.

Sequential treatment with bortezomib plus dexamethasone followed by autologous hematopoietic stem cell transplantation in patients with multiple myeloma.

Zheng D, Li J, Huang BH, Liu JR, Zou WY, Su C.

Chin Med J (Engl). 2012 Dec;125(24):4454-9.

PMID:
23253719
[PubMed - indexed for MEDLINE]
17.

Early response-based intensification of primary therapy in newly diagnosed multiple myeloma patients who are eligible for autologous stem cell transplantation: phase II study.

Ahn SY, Jung SH, Joo YD, Lee WS, Lee SM, Choi CW, Kim SJ, Kim K, Lee JJ; Korean Multiple Myeloma Working Party.

Ann Hematol. 2014 Sep;93(9):1571-7. doi: 10.1007/s00277-014-2067-3. Epub 2014 Apr 12.

PMID:
24728664
[PubMed - indexed for MEDLINE]
18.

Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma: a retrospective study.

Kaufman JL, Nooka A, Vrana M, Gleason C, Heffner LT, Lonial S.

Cancer. 2010 Jul 1;116(13):3143-51. doi: 10.1002/cncr.25143.

PMID:
20564642
[PubMed - indexed for MEDLINE]
Free Article
19.

Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival.

Palumbo A, Attal M, Roussel M.

Clin Cancer Res. 2011 Mar 15;17(6):1253-63. doi: 10.1158/1078-0432.CCR-10-1925. Review.

PMID:
21411441
[PubMed - indexed for MEDLINE]
Free Article
20.

Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study.

Rosiñol L, Oriol A, Teruel AI, Hernández D, López-Jiménez J, de la Rubia J, Granell M, Besalduch J, Palomera L, González Y, Etxebeste MA, Díaz-Mediavilla J, Hernández MT, de Arriba F, Gutiérrez NC, Martín-Ramos ML, Cibeira MT, Mateos MV, Martínez J, Alegre A, Lahuerta JJ, San Miguel J, Bladé J; Programa para el Estudio y la Terapéutica de las Hemopatías Malignas/Grupo Español de Mieloma (PETHEMA/GEM) group.

Blood. 2012 Aug 23;120(8):1589-96. Epub 2012 Jul 12.

PMID:
22791289
[PubMed - indexed for MEDLINE]
Free Article
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk